Price
No data yet.
Social Signal Score
Analyst Ratings
10 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Paul-Peter Tak
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 55
- Beta
- -0.47
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 3.36
Financials
Revenue
$0.00-100.0%Net Income
$-38.91MEBITDA
$-37.01MFree Cash Flow
$-17.25MEPS (diluted)
$-0.52Shares Outstanding (diluted)
74.13M+296.1%Operating Expenses
$26.75MCash & Debt
$201.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-38.18M | $-0.72 |
| 2024 | $0.00 | $-55.18M | $-1.74 |
| 2023 | $0.00 | $-37.94M | $-1.31 |
| 2022 | $125.0K | $-18.79M | $-0.10 |
| 2021 | $125.0K | $-36.12M | $-1.91 |
| 2020 | $125.0K | $-17.68M | $-1.18 |
| 2019 | $125.0K | $-8.24M | $-0.43 |
Valuation
CADLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100-23.08%Social Signal Score
Mentions (7)
- Newsglobenewswire.com·6d ago·Neutral
…ec Treatment in Localized Prostate Cancer at ASTRO 2026 NEEDHAM, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the presentation of new biomarker data from its completed phase 3 clinical trial of aglatimagene besadenovec (aglatimagene) in patients with localized intermediate- …
View source ↗ - Newsseekingalpha.com·13d ago·Positive
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 Candel Therapeutics, Inc. is upgraded from Buy to Strong Buy, driven by phase 3 success in localized prostate cancer. The company's aglatimagene met the primary endpoint in a pivotal trial, reducing disease recurrence risk by 30% and supporting a BLA filing in Q4 2026. Upcoming catalysts include phase 3 biomarker data at ASTRO 2026 and advancing aglatimagene in metastatic NSCLC with the AURORA trial.
View source ↗ - Newszacks.com·20d ago·Negative
4 Prostate Cancer Drug Stocks to Watch During Awareness Month Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.
View source ↗ - Newsglobenewswire.com·26d ago·Neutral
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company's Board of Directors (Board) effective September 8, 2026.
View source ↗ - Newsglobenewswire.com·41d ago·Neutral
Candel Therapeutics to Present at September Investor Conferences NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
View source ↗ - Newsmarketbeat.com·54d ago·Positive
Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.30 per share
Typical surprise -23.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.52 vs $-0.24miss
- Thu, May 14$-0.14 vs $-0.22beat
- Thu, Mar 12$-0.54 vs $-0.24miss
- Thu, Nov 13$-0.21 vs $-0.17miss
- Thu, Aug 14$-0.09 vs $-0.17beat
- Tue, May 13$0.13 vs $-0.24beat
Estimates and results for CADL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CADL officers and directors.
- Bought
- $3.0m
- Sold
- $5.9m
1 trade
23 trades
- Tak Paul Petersold
- Tak Paul Petersold
- Tyagarajan Seshusold
- Barone Francescasold
- Tyagarajan Seshusold
- Manning Paul Bbought
- Nichols William Garrettsold
- Nichols William Garrettsold
76 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CADL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.